9% af de Zenapax- behandlede patienter, men antistofferne syntes ikke at påvirke effekt, sikkerhed, daclizumab serumniveauer eller andre af de undersøgte klinisk relevante parametre.
Antibodies to daclizumab developed in approximately 9% of Zenapax- treated patients in clinical studies but did not appear to affect efficacy, safety, serum daclizumab levels, or any other clinically relevant parameter examined.